Literature DB >> 23695201

Clinical presentation, diagnosis, pathogenesis and treatment options for lymphocytic colitis (Review).

Magdy El-Salhy1, Doris Gundersen, Jan Gunnar Hatlebakk, Trygve Hausken.   

Abstract

Lymphocytic colitis (LC) is characterized by chronic or relapsing non-bloody watery diarrhea and a macroscopically normal colon. However, histopathological examination of colonic biopsy samples reveals an increased intraepithelial infiltration of lymphocytes (≥20/100 enterocytes), and increased inflammatory cells within the lamina propria, but with a normal mucosal architecture. The reported prevalence of LC varies from 14.2 to 45 per 100,000 individuals, while its reported incidence is between 0.6 and 16 per 100,000 individuals. LC has a high rate of spontaneous symptomatic remission and is not associated with an increased risk of colon cancer or inflammatory bowel disease. The diagnosis is based on the histopathological findings. The density of colonic chromogranin A-positive cells provides an effective diagnostic tool with high sensitivity and specificity in both the right and left colon. Gastrointestinal infections, drugs, and/or autoimmunity may trigger chronic colonic low-grade inflammation. Colonic nitric oxide, serotonin and peptide YY (PYY) cell densities are markedly increased in patients with LC. It has been hypothesized that the low-grade inflammation in LC through the endocrine-immune axis causes this increase. It has been postulated further that these abnormalities in the neuroendocrine system of the colon are responsible for the diarrhea observed in patients with LC. The benign course and rate of spontaneous remission of LC denotes that drugs with severe side-effects should be avoided if possible. The drug cost and drug coverage may also be limiting factors for some patients. These aspects should be taken into account when making decisions regarding treatment options.

Entities:  

Mesh:

Year:  2013        PMID: 23695201     DOI: 10.3892/ijmm.2013.1385

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  7 in total

1.  Lymphocytic colitis complicated by a mass in the terminal ileum.

Authors:  Chee-Kin Hui
Journal:  Singapore Med J       Date:  2015-05       Impact factor: 1.858

2.  Proinflammatory Sulfur-Reducing Bacteria Are More Abundant in Colonic Biopsies of Patients with Microscopic Colitis Compared to Healthy Controls.

Authors:  Valentine Millien; Daniel Rosen; Jason Hou; Rajesh Shah
Journal:  Dig Dis Sci       Date:  2018-10-15       Impact factor: 3.199

Review 3.  Gastrointestinal neuroendocrine peptides/amines in inflammatory bowel disease.

Authors:  Magdy El-Salhy; Tefera Solomon; Trygve Hausken; Odd Helge Gilja; Jan Gunnar Hatlebakk
Journal:  World J Gastroenterol       Date:  2017-07-28       Impact factor: 5.742

4.  Changes in enteroendocrine and immune cells following colitis induction by TNBS in rats.

Authors:  Magdy El-Salhy; Jan Gunnar Hatlebakk
Journal:  Mol Med Rep       Date:  2016-10-31       Impact factor: 2.952

Review 5.  Drug Exposure and the Risk of Microscopic Colitis: A Critical Update.

Authors:  Alfredo J Lucendo
Journal:  Drugs R D       Date:  2017-03

6.  Abnormal differentiation of stem cells into enteroendocrine cells in rats with DSS-induced colitis.

Authors:  Magdy El-Salhy; Kazuo Umezawa; Jan Gunnar Hatlebakk; Odd Helge Gilja
Journal:  Mol Med Rep       Date:  2017-03-01       Impact factor: 2.952

7.  Abnormalities in endocrine and immune cells are correlated in dextran‑sulfate‑sodium‑induced colitis in rats.

Authors:  Magdy El-Salhy; Jan Gunnar Hatlebakk; Odd Helge Gilja
Journal:  Mol Med Rep       Date:  2016-12-12       Impact factor: 2.952

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.